Chimeric Antigen Receptor T Cells (CAR-T)

DRUG4 trials

Sponsors

PersonGen BioTherapeutics (Suzhou) Co., Ltd., Institute of Hematology & Blood Diseases Hospital, China, Shanghai Tongji Hospital, Tongji University School of Medicine, Chulalongkorn University

Conditions

Acute Myeloid LeukemiaB-cell Acute Lymphoblastic LeukemiaCARRelapsed or Refractory Aggressive B-cell LymphomaRelapsed/Refractory Multiple Myeloma (MM)

Early Phase 1

Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Not yet recruitingNCT07458659

Chulalongkorn UniversityRelapsed/Refractory Multiple Myeloma (MM)

Start: 2026-06-01End: 2029-06-01Target: 3Updated: 2026-03-09

Phase 1

A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Not yet recruitingNCT07043218

Shanghai Tongji Hospital, Tongji University School of MedicineB-cell Acute Lymphoblastic Leukemia

Start: 2025-07-10End: 2027-06-30Target: 36Updated: 2025-06-29

Phase 2

Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma

RecruitingNCT06996132

Institute of Hematology & Blood Diseases Hospital, ChinaRelapsed or Refractory Aggressive B-cell Lymphoma

Start: 2025-05-09End: 2027-12-30Target: 25Updated: 2025-06-17

Unknown Phase

TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia

PersonGen BioTherapeutics (Suzhou) Co., Ltd.Acute Myeloid Leukemia, CAR

Start: 2019-12-09End: 2023-12-31Target: 5Updated: 2021-03-08